

## Vystar Corporation



### Vytex<sup>®</sup> Natural Rubber Latex is the Future of Latex

[vytex.com](http://vytex.com)

**Industry:** Manufacturers producing over 40,000 products made from natural rubber latex including gloves, condoms, foam bedding, adhesives, balloons and threads. Latex market is estimated at 1.3 million metric tons valued at over \$2.6 billion\*.

#### Executive Officers:

William R. Doyle,  
President and CEO  
Sandra Parker,  
Executive Vice President,  
Business Development &  
Marketing  
Matt Clark,  
Vice President, Technical  
Sales

#### Board of Directors:

J. Douglas Craft  
Joseph C. Allegra, M.D.  
Dean Waters  
Mitsy Y. Mangum

#### Revenues:

2009 Projected: \$50K  
2010 Projected: \$1.67MM  
2011 Projected: \$5.645MM

#### Financing Sought:

\$2.0 Million at \$2.00 per common share, plus 500,000 warrants at \$1.50 exercisable within 12 months and 500,000 at \$3.25 exercisable within 24 months on matching units

#### Use of Proceeds:

Working capital, sales and marketing of our products and other general corporate purposes.

**Business Description:** Up to 17 percent of healthcare workers and up to 6 percent of the general population experience allergic reactions or sensitivities to natural rubber latex. **Vystar<sup>®</sup> Corporation** has a solution for the growing problem of latex allergy, **Vytex<sup>®</sup> Natural Rubber Latex (NRL)**, a new, safer latex. Accelerated use of latex gloves to protect against infectious diseases over the past two decades has resulted in the large number of healthcare workers affected by latex allergies. A greater risk is with the general population that is not aware of the allergy until they come in contact with latex during a medical procedure or latex products in everyday life. **Vytex** NRL addresses the source by removing the antigenic proteins believed to be associated with latex allergy to virtually undetectable levels. **Vytex** NRL is commercially available with over 55 manufacturing evaluations underway for gloves, foam bedding, adhesives, balloons and condoms. The first condom made with **Vytex** NRL is available for sale with the lowest protein claim for a condom on the market, less than 2 micrograms per dm<sup>2</sup> of antigenic protein.

**Unique Value Proposition:** **Vytex** NRL is a standardized source material for the production of natural rubber products using "green" chemistry to modify NRL and significantly reduce its antigenic protein content believed to be associated with latex allergies without compromising the excellent qualities of NRL. **Vytex** NRL is eco-friendly, all natural, biodegradable, contains no VOCs or known or suspected human carcinogens unlike petroleum-based synthetic alternatives.

#### Key Success Factors:

- Mount a concerted public relations and marketing effort to drive demand for **Vytex** NRL to key manufacturers identified as early adopters and focused consumer groups.
- Identify and convince targeted healthcare workers who are traditionally early adopters to demand the value advantages of **Vytex** NRL.
- Pursue ASTM affirmative testing to support US Food and Drug Administration submission by manufacturers of equivalency.
- Worldwide distribution in all types of products will be achieved through licensing agreements with Revertex and other strategic latex processors.
- Recognition by latex industry and biotech industry as key market mover.

**Status:** **Vytex** NRL became commercially available in June 2008 with the execution of a toll manufacturing agreement with Revertex (Malaysia), the largest producer of prevulcanized lattices. Currently over 55 manufacturing evaluations are in progress. Alatech Healthcare (Eufaula, AL) has received two US FDA 510(k) clearances to market condoms and exam gloves made with **Vytex** NRL. The Envy<sup>™</sup> condom made with **Vytex** NRL with the lowest allowable protein claim (less than 2 micrograms per dm<sup>2</sup> of antigenic protein) is available for retail sale.

**Forecast Revenue:** Projected revenue: 2009 \$ 50,000; 2010 \$ 1.67 million; 2011 \$ 5.645 million

**Existing debt:** Minimal debt.

**Previous investment amount:** Raised approximately \$7.8 million through three private placements.

**Funds sought:** \$2.0 million at \$2.00 per common share plus 500,000 warrants at \$1.50 exercisable within 12 months and 500,000 warrants at \$3.25 exercisable within 24 months.

**Application of funds:** Working capital, sales and marketing of our products and other general corporate purposes.

**Funding structure preferred:** Currently we are selling Common Stock at a minimum of 20,000 shares at a price of \$2.00. We prefer a larger investment that includes multiple units and the warrant option.

**Exit Strategy:** Vystar received SEC clearance in August 2009 and is currently awaiting DTC approval. No investment dollars are being raised by Vystar in the current IPO. Strategy may include acquisition by a large Latex Manufacturing company seeking to participate in the market shift to this ultra low protein latex.

**Documents Available:** Private Placement Memorandum, Power Point, Articles

\* 2006 International Rubber Study Group  
Vystar<sup>®</sup>, Vytex<sup>®</sup> and related marks are registered trademarks of Vystar Corporation, Duluth, GA 30096 USA